A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 905 participants.

Also called NCT02681094

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 905 participants (enrolled count) (from the registry)
Sponsor
  • AstraZeneca Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02681094
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Czechia, Germany, Mexico, Russia (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02681094. Randomized; triple masking; primary purpose treatment. Start 2016-02-26 (actual); primary completion 2017-07-15 (actual). Results posted on 2018-10-10.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Multi-Center, Randomized, Double-Blind, Phase III Trial to Evaluate the Safety and Efficacy of Saxagliptin Co-administered With Dapagliflozin Compared to Saxagliptin or Dapagliflozin All Given as add-on Therapy to Metformin in Subject With Type 2 Diabetes
Condition
Type 2 Diabetes Mellitus
Condition
Inadequate Glycaemic Control
Intervention (Drug)
Dapagliflozin
Intervention (Drug)
Placebo for Dapagliflozin
Intervention (Drug)
Saxagliptin
Intervention (Drug)
Placebo for Saxagliptin
Lead sponsor
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct02681094
Content hash
ad4c066c4f21f3d8699a3b8e809bf8ca041151e70d1310368fdc4817cd3774eb